What is the BiotechSign catalyst score for RARE?

RARE currently has a BiotechSign catalyst score of 57/100 and grade C. Scores combine FDA, clinical trial, insider, dilution, sentiment, short interest, and convergence signals.

What signals does BiotechSign track for RARE?

BiotechSign tracks 0 active signals for RARE, including 0 PDUFA signals, 0 insider buying signals, and 0 clinical trial signals when available.

When was the RARE catalyst page updated?

This RARE page was refreshed from BiotechSign data on 2026-07-19.

You have used your free lookups for today

Upgrade to BiotechSign Pro for unlimited company access, full signal history, watchlist alerts, and 125+ PDUFA dates.

Upgrade to Pro →← Back to screener

← Back to Screener

RARE — Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

Rare DiseaseScore: 57/100Full Profile

What is the current RARE catalyst setup?

RARE is tracked by BiotechSign with a current catalyst score of 57/100 and grade C. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.

Company SnapshotUpdated 2026-07-19

As of 2026-07-19, Ultragenyx Pharmaceutical (RARE) has a BiotechSign Catalyst Score of 57/100, rated C. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.

This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).

Analyst Summary

Verified 2026-04-11

Ultragenyx Pharmaceutical (RARE) is the lead sponsor of 17 active clinical trials listed on ClinicalTrials.gov^[4], including 9 Phase 3^[1], 4 Phase 2^[2], 1 Phase 1^[3].

Trial NCT05768854^[5] evaluates Bisphosphonate in Osteogenesis Imperfecta with a target enrollment of 69 participants. Trial NCT05933200^[6] evaluates Triheptanoin in Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) with a target enrollment of 69 participants. Trial NCT05345171^[7] evaluates DTX301 in OTC Deficiency with a target enrollment of 32 participants.

RARE has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[8].

Sources

ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov · NCT05768854 (2026-02-25) ↗
ClinicalTrials.gov · NCT05933200 (2026-04-07) ↗
ClinicalTrials.gov · NCT05345171 (2026-02-17) ↗
SEC EDGAR · 0001515673 (2026-04-11) ↗

Not financial advice. BiotechSign scores are for informational purposes only and do not constitute investment recommendations. Always do your own due diligence before making investment decisions.